Aripiprazole and olanzapine on senile dementia of the alzheimer type: A control study

doi:10.3969/j.issn.1004-583X.2022.08.004

Abstract

Abstract:

Objective To assess the effectiveness and safety of aripiprazole and olanzapine on senile dementia of the alzheimer type (SDAT). Methods A total of 86 SDAT patients visited in the Eighth Hospital of Shijiazhuang from November 2020 to November 2021 were enrolled and randomly assigned into the observation group and the control group. The patients were managed by supportive treatment based on etiology of delirium, the observation group was treated with oral or sublingual administration of aripiprazole at dose range 2.50-10.00 mg/d, and the control group with olanzapine at dose range 1.25-10.00 mg/d. The aiming was to compare the clinical efficacy and safety. Results The treatment efficiency of patients with hypoactive SDAT in the observation group was better than that in the control group (P<0.05). The difference was not statistically significant in the treatment efficiency of hyperactive SDAT and mixed SDAT between groups (all P>0.05). There was no interruption of treatment due to serious adverse reactions in both groups during the observation period. Conclusion For SDAT patients, aripiprazole and olanzapine are safe to use. The low-dose aripiprazole is superior to olanzapine for hypoactive SDAT patients. Moreover, both low-dose, short-course of aripiprazole and olanzapine were well tolerated for these patients.

Key words: dementia, delirium, aripiprazole, olanzapine

CLC Number:

R749.16

Li Ping, Xu Manhua, He Lanying, Wang Lifeng, Zhang Pei, Song Lihua. Aripiprazole and olanzapine on senile dementia of the alzheimer type: A control study[J]. Clinical Focus, 2022, 37(8): 699-703.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.08.004

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I8/699

Figures/Tables 6

组别	例数	性别[例(%)]		年龄(岁)	教育程度[例(%)]
组别	例数	男	女	年龄(岁)	小学及以下	中学含中专	大学含专科
对照组	40	26(65.0)	14(35.0)	72.65±5.21	22(55.0)	16(40.0)	2(5.0)
观察组	40	28(70.0)	12(30.0)	72.63±5.05	24(60.0)	14(35.0)	2(5.0)
统计值		χ²=0.228		$t$ =0.022	χ²=0.359
$P$ 值		0.633		0.983	0.929

组别	例数	性别[例(%)]		年龄(岁)	教育程度[例(%)]
组别	例数	男	女	年龄(岁)	小学及以下	中学含中专	大学含专科
对照组	40	26(65.0)	14(35.0)	72.65±5.21	22(55.0)	16(40.0)	2(5.0)
观察组	40	28(70.0)	12(30.0)	72.63±5.05	24(60.0)	14(35.0)	2(5.0)
统计值		χ²=0.228		$t$ =0.022	χ²=0.359
$P$ 值		0.633		0.983	0.929

组别	例数	治疗前	治疗后
对照组	40	15.38±2.61	15.15±2.67
观察组	40	15.68±2.74	15.53±2.57
$t$ 值		0.502	0.640
$P$ 值		0.617	0.524

组别	例数	治疗前	治疗后
对照组	40	15.38±2.61	15.15±2.67
观察组	40	15.68±2.74	15.53±2.57
$t$ 值		0.502	0.640
$P$ 值		0.617	0.524

组别	例数	治疗前	治疗后
组别	例数	治疗前	第1天	第2天	第3天	第7天	第14天
对照组	16	36.00±1.63	35.31±1.85	35.06±1.77	33.81±2.04^*	23.81±8.57^*	20.44±7.12^*
观察组	14	37.00±1.30	36.29±0.99	34.79±1.05^*	14.42±1.01^*△	11.50±1.29^△	11.21±1.05^△
组间			$F$ =55.224 $P$ =0.000
不同时点			$F$ =315.691 $P$ =0.000
组间·不同时点			$F$ =62.847 $P$ =0.000

组别	例数	治疗前	治疗后
组别	例数	治疗前	第1天	第2天	第3天	第7天	第14天
对照组	16	36.00±1.63	35.31±1.85	35.06±1.77	33.81±2.04^*	23.81±8.57^*	20.44±7.12^*
观察组	14	37.00±1.30	36.29±0.99	34.79±1.05^*	14.42±1.01^*△	11.50±1.29^△	11.21±1.05^△
组间			$F$ =55.224 $P$ =0.000
不同时点			$F$ =315.691 $P$ =0.000
组间·不同时点			$F$ =62.847 $P$ =0.000

组别	例数	治疗前	治疗后
组别	例数	治疗前	第1天	第2天	第3天	第7天	第14天
对照组	14	35.86±1.51	34.21±1.05^*	30.21±1.42^*	16.00±4.52	15.50±3.82	13.50±2.44
观察组	15	36.20±1.47	33.87±1.73^*	29.93±1.39^*	18.13±3.44^*	15.67±3.22^*	13.20±2.54^*
组间			$F$ =0.213 $P$ =0.648
不同时点			$F$ =615.086 $P$ =0.000
组间·不同时点			$F$ =1.345 $P$ =0.269

组别	例数	治疗前	治疗后
组别	例数	治疗前	第1天	第2天	第3天	第7天	第14天
对照组	14	35.86±1.51	34.21±1.05^*	30.21±1.42^*	16.00±4.52	15.50±3.82	13.50±2.44
观察组	15	36.20±1.47	33.87±1.73^*	29.93±1.39^*	18.13±3.44^*	15.67±3.22^*	13.20±2.54^*
组间			$F$ =0.213 $P$ =0.648
不同时点			$F$ =615.086 $P$ =0.000
组间·不同时点			$F$ =1.345 $P$ =0.269

组别	例数	治疗前	治疗后
组别	例数	治疗前	第1天	第2天	第3天	第7天	第14天
对照组	10	35.10±2.33	35.10±2.33^*	30.70±2.36^*	19.90±6.74^*	17.70±4.52	14.60±2.32^*
观察组	11	35.55±1.51	35.55±1.51^*	32.91±3.21^*	19.18±7.49^*	14.45±2.58^*	14.18±2.04
组间			$F$ =0.035 $P$ =0.854
不同时点			$F$ =233.243 $P$ =0.000
组间·不同时点			$F$ =1.970 $P$ =0.165

组别	例数	治疗前	治疗后
组别	例数	治疗前	第1天	第2天	第3天	第7天	第14天
对照组	10	35.10±2.33	35.10±2.33^*	30.70±2.36^*	19.90±6.74^*	17.70±4.52	14.60±2.32^*
观察组	11	35.55±1.51	35.55±1.51^*	32.91±3.21^*	19.18±7.49^*	14.45±2.58^*	14.18±2.04
组间			$F$ =0.035 $P$ =0.854
不同时点			$F$ =233.243 $P$ =0.000
组间·不同时点			$F$ =1.970 $P$ =0.165

组别	低活动型		高活动型		混合型
组别	有效	无效	有效	无效	有效	无效
对照组	10	6	13	1	9	1
观察组	14	0	14	1	10	1
χ²值	-		-		-
$P$ 值	0.046		1.000		1.000

组别	低活动型		高活动型		混合型
组别	有效	无效	有效	无效	有效	无效
对照组	10	6	13	1	9	1
观察组	14	0	14	1	10	1
χ²值	-		-		-
$P$ 值	0.046		1.000		1.000

References 25

[1]	何华英, 孔婵, 徐嘉琦, 等. 加拿大安大略注册护士协会《老年人的谵妄、痴呆、抑郁:评估和护理》临床实践指南解读——痴呆[J]. 护理研究, 2020, 34(12):2057-2061.
[2]	Yerra S, Yarra P. Best practices to prevent delirium in hospitalised patients[J]. Evidence Based Nursing, 2021, 25(1):14. doi: 10.1136/ebnurs-2020-103336 URL
[3]	Strijbos MJ, Steunenberg B, van der Mast RC, et al. Design and methods of the Hospital Elder Life Program (HELP), a multicomponent targeted intervention to prevent delirium in hospitalized older patients: Efficacy and cost-effectiveness in Dutch health care[J]. BMC Geriatr, 2013, 13:78. doi: 10.1186/1471-2318-13-78 pmid: 23879226
[4]	温成成, 秦家碧. 老年痴呆患者谵妄的研究现状及护理进展[J]. 海南医学, 2019, 30(4):526-529.
[5]	Shenvi C, Kennedy M, Austin CA, et al. Managing delirium and agitation in the older emergency department patient: The ADEPT tool[J]. Ann Emerg Med, 2020, 75(2):136-145. doi: S0196-0644(19)30609-2 pmid: 31563402
[6]	胡华, 邓伟, 杨辉, 等. 奥氮平与氟哌啶醇治疗老年性谵妄的随机对照观察[J]. 中国临床康复, 2006, 10(42):188-190.
[7]	冼易平, 王英. 奥氮平与利培酮治疗老年期谵妄患者的对照研究[J]. 临床精神医学杂志, 2011, 21(6):402-403.
[8]	康明秀. 奥氮平的精神科临床应用及其不良反应[J]. 精神医学杂志, 2010, 23(3):235-237.
[9]	Streim JE, Porsteinsson AP, Breder CD, et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease[J]. Am J Geriatr Psychiatry, 2008, 16(7):537-550. doi: 10.1097/JGP.0b013e318165db77 pmid: 18591574
[10]	Mintzer JE, Tune LE, Breder CD, et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: A multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses[J]. Am J Geriatr Psychiatry, 2007, 15(11):918-931. doi: 10.1097/JGP.0b013e3181557b47 URL
[11]	干雪琴, 张文武, 王伊娜, 等. 住院痴呆患者伴发谵妄的危险因素分析[J]. 中国现代医生, 2017, 55(35):72-74.
[12]	Reynish EL, Hapca SM, De Souza N, et al. Epidemiology and outcomes of people with dementia, delirium, and unspecified cognitive impairment in the general hospital: Prospective cohort study of 10, 014 admissions[J]. BMC Medicine, 2017, 15(1).
[13]	Zou C, Mei X, Li X, et al. Effect of light therapy on delirium in older patients with Alzheimer's disease-related dementia[J]. J Psychiatr Res, 2022, 149:124-127. doi: 10.1016/j.jpsychires.2022.03.003 pmid: 35272209
[14]	Abraham MP, Hinds M, Tayidi I, et al. Quetiapine for delirium prophylaxis in high-risk critically ill patients[J]. Surgeon, 2021, 19(2):65-71. doi: 10.1016/j.surge.2020.02.002 URL
[15]	Ostuzzi G, Gastaldon C, Papola D, et al. Pharmacological treatment of hyperactive delirium in people with COVID-19: Rethinking conventional approaches[J]. Ther Adv Psychopharmacol, 2020, 10:666459025.
[16]	Boettger S, Jenewein J, Breitbart W. Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects[J]. Palliative and Supportive Care, 2015, 13(4):1079-1085. doi: 10.1017/S1478951514001059 pmid: 25191793
[17]	耿晓锋. 奥氮平治疗器质性精神障碍的临床疗效[J]. 临床合理用药杂志, 2015, 8(24):72-73.
[18]	周立峰. 奥氮平治疗急性中风后谵妄的临床观察[J]. 海峡药学, 2010, 22(5):121-122.
[19]	赵焕华, 尤年兴, 晏云兴, 等. 奥氮平治疗谵妄38例临床分析[J]. 临床精神医学杂志, 2002, (3):156.
[20]	宋昌军, 党卫军, 李娟, 等. 奥氮平治疗综合医院急性谵妄患者临床疗效观察[J]. 贵州医药, 2021, 45(1):54-55.
[21]	遇培彤. 非典型抗精神病药与氟哌啶醇对谵妄的疗效和安全性[D]. 沈阳: 中国医科大学, 2019.
[22]	Yunusa I, Alsumali A, Garba AE, et al. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: A network meta-analysis[J]. JAMA Netw Open, 2019, 2(3):e190828. doi: 10.1001/jamanetworkopen.2019.0828 URL
[23]	Madhusoodanan S, Shah P. Management of psychosis in patients with Alzheimer's disease: Focus on aripiprazole[J]. Clin Interv Aging, 2008, 3(3):491-501. pmid: 18982919
[24]	Lodewijckx E, Debain A, Lieten S, et al. Pharmacologic treatment for hypoactive delirium in adult patients: A brief report of the literature[J]. J Am Med Dir Assoc, 2021, 22(6):1313-1316. doi: 10.1016/j.jamda.2020.12.037 pmid: 33549562
[25]	Cummings JL, Tong G, Ballard C. Treatment combinations for Alzheimer's disease: Current and future pharmacotherapy options[J]. J Alzheimers Dis, 2019, 67(3):779-794. doi: 10.3233/JAD-180766 pmid: 30689575